EasyBlog

This is some blog description about this site

COPENHAGEN, MARCH 24 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that Antibiotx has been rewarded a grant from Innovation Fund Denmark to further explore ATx201’s influence on biomarkers in inflammatory disease.

Specific inflammatory pathways appear to be important for atopic dermatitis severity and ATx201 shows promising assets affecting these pathways. Based on this rationale, Innovation Fund Denmark has granted AntibioTx the means to investigate ATx201 in a well-established clinical model”.

About Atopic dermatitis
Atopic dermatitis is one of the most common skin diseases. It is estimated that 5–20% of the population worldwide is suffering from atopic dermatitis. The disease is believed to develop from a complex interplay of environmental and immunologic factors and is often associated with allergy and asthma. Characteristic AD symptoms are itchy skin (pruritus) and inflammation causing redness, dry skin, crusting, vesicle formation, and swelling. Numerous studies have found that AD has a major impact on physical and psychological well-being and has a psychological impact on close relatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Source: Thomas Bieber. Atopic Dermatitis, Mechanisms of Disease. New England Journal of Medicine, 2008

Continue reading

AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders, has announced the appointment of Dr. Phillipe Prokocimer as new Chief Medical Officer. Dr. Prokocimer brings more than 30 years of experience within antimicrobial drug development and has been involved in successful FDA approval of 6 New Drug Applications including 5 antibacterial compounds: Doripenem (Doribax®), Quinupristin/dalfopristin (Synercid®), Sparfloxacin (Zagam®), Clarithromycin (Biaxin®) and Tedizolid Phosphate (Sivextros®). Dr. Prokocimer will join as a full-time Chief Medical Officer for AntibioTx and lead the clinical development team.

The CEO of AntibioTx, Rasmus Toft-Kehler, commented: “Dr. Prokocimer’s experience and track record in clinical development is exceptional and of significant importance to AntibioTx”, and further added; ”Dr. Prokocimer joins the company at an exciting time and will be playing a key role in the design and execution of upcoming Phase II trials”.

Dr. Prokocimer has been the Chief Medical Officer of Trius Therapeutics from 2007 until its acquisition by Cubist in 2014. Here he was appointed Senior Vice President of Clinical Development at Cubist until it was acquired by Merck in 2015. At Merck, he kept a position as Senior Vice President of Clinical Development as Head of the San Diego site. Dr. Prokocimer received his medical degree from the School of Medicine in Paris, France and a Post-Doctoral Research Fellowship from Stanford University.

The appointment of Dr. Prokocimer is well aligned with the company’s strategy to expand its US presence. AntibioTx recently established a US subsidiary and seeks to build a clinical development team with a basis in San Diego, California.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, FEBRUARY 15, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders today announced that Lutz Wevelsiep, Ph.D. will be appointed as AntibioTx new VP of Drug Regulatory Affairs.

“Lutz will manage and oversee the Company’s international filings and relations with regulatory authorities” said Rasmus Toft-Kehler, CEO of AntibioTx ”Lutz brings more than 25 years’ of experience and has a proven track record from both multinational and start-up companies thus we feel confident that we have found the right person in charge of our overall regulatory strategies”. 

Dr. Wevelsiep has been Head of Global Regulatory Affairs for 16 years at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®). Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, NOVEMBER 14, 2016 – Worldwide we a see a need for action against AMR and AntibioTx is highly aware of something has to be done. The 10th Berlin Conference on Life Sciences takes place 24th February 2017. 
The conference will focus on the problems we face combating AMR; such as the need for new R&D and improve clinical, financial and approval pathway in order to safeguard healthcare in the future.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, SEPTEMBER 19, 2016 – A 28-day repeat dosing study in Göttingen minipigs concluded that proprietary formulations of ATx201 are well tolerated and leads to very low systemic exposure. BioAdvice, a leading GLP and GMP contract research organization located in Denmark, conducted the study. The outcome confirms previous studies suggestive of the favorable safety profile of ATx201.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News